POPular TAVI compared this strategy to oral anticoagulation plus clopidogrel for 3 months after TAVR

Patients with atrial fibrillation on oral anticoagulation (OAC) therapy who underwent transcatheter aortic valve replacement (TAVR) and continued treatment with OAC alone had a lower rate of serious bleeding at 1-year follow-up than patients who received OAC plus clopidogrel for 3 months after TAVR, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.